Page 81 - Zai Lab News Today

Smartphone technology in bid to revolutionise early detection of kidney disease Thousands of patients to benefit from smartphone app that allows them to transmit results to their GP in minutes without leaving home. From: AI) that turns a smartphone camera into a clinical-grade tool to detect early kidney disease. NHSX, the digital transformation arm of the NHS, is supporting Healthy.io to offer 500,000 patients technology-supported home-testing kits over the next 3 years. More than 3,500 pa...

/PRNewswire/ -- Qiming Venture Partners ("Qiming") today announced the final close of our RMB Fund VI at RMB 2.852 billion. Currently, Qiming has $5.9 billion...

(2) Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The BLA submission is based on data from the Phase 2 POD1UM-202 trial evaluatin...

Previous image Next image Three MIT computer science faculty members have been elected as fellows of the Association for Computing Machinery (ACM). The new fellows are among 95 ACM members recognized as the top 1 percent for their outstanding accomplishments in computing and information technology and/or outstanding service to ACM and the larger computing community. Fellows are nominated by their peers, with nominations reviewed by a distinguished selection committee. Anantha Chandrakasan is d...

Turning Point and Zai Lab Broaden Collaboration Turning Point Therapeutics, Inc. San Diego, California, UNITED STATES Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point’s MET/SRC/CSF1R Inhibitor, in Greater China Turning Point to Receive $25 Million Upfront, with Up to Approximately $336 Million in Potential Milestone Payments and Royalties SAN DIEGO, SHANGHAI, China and SAN FRANCISCO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Turning Point T...

AI at the forefront of efforts to treat coronavirus patients Patients with COVID-19 are set to benefit from faster treatment, improved outcomes and shorter hospital stays thanks to the use of the latest artificial intelligence. From: Increased speed and accuracy in diagnosis can lead to early medical intervention and save lives NHSX, a unit tasked with driving the digital transformation of care in the NHS, has brought together over 40,000 CT scans, MRIs and X-rays from more than 10,000 pati...

argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for efgartigimod in generalized myasthenia gravis (gMG) Initiated 50-patient gMG bridging study of subcutaneous (SC) efgartigimod based on FDA feedback Enrolled first 30 patients, necessary for go/no-...

Top 25 CPA and Advisory Firm Carr, Riggs & Ingram Welcomes Russell Thompson Butler & Houston, LLP Top 25 CPA and Advisory Firm Carr, Riggs & Ingram Welcomes Russell Thompson Butler & Houston, LLP MOBILE, Ala., Jan. 7, 2021 /PRNewswire/ — After years of providing their clients with personalized financial guidance, Russell Thompson Butler & Houston, LLP (RTBH) has merged with nationally ranked CPA and advisory firm Carr, Riggs & Ingram, LLC (CRI). The RTBH team joins more than 1,900 CRI profes...

Press release content from PR Newswire. The AP news staff was not involved in its creation. Qiming Venture Partners’ Portfolio Company APT Medical Listed on STAR Board of Shanghai Stock Exchange January 7, 2021 GMT SHANGHAI, Jan. 7, 2021 /PRNewswire/ -- Qiming Venture Partners’ portfolio company APT Medical (SHSE: 688617) today successfully listed on the Science and Technology Innovation Board (the STAR Board) of Shanghai Stock Exchange. The issue price is CNY 74.46 per share. The stock ope...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China Zai Lab Limited; argenxJanuary 6, 2021 GMT Collaboration to expand and accelerate global development of efgartigimod; expected to allow argenx to more rapidly advance new potential indications into clinical development each year Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater ...